
    
      In this study, there are two sub-studies in order to define secondary endpoints.

        1. Pharmacokinetics study of Mycophenolic acid

        2. Identify biomarkers for therapy-resistant prediction.

        3. Identify biomarkers for predicting a loss of kidney function.
    
  